COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of SHR4010 in Patients With Hemodialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04099927
Recruitment Status : Active, not recruiting
First Posted : September 23, 2019
Last Update Posted : May 22, 2020
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:
The study is being conducted to evaluate the safety and pharmacokinetics of SHR0410 in patients with hemodialysis.

Condition or disease Intervention/treatment Phase
Pruritus Drug: SHR0410 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: SHR0410 monotherapy
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label Clinical Study on Safety and Pharmacokinetics of SHR0410 Injection for Multiple Administration in Hemodialysis Patients
Actual Study Start Date : July 28, 2019
Actual Primary Completion Date : April 20, 2020
Estimated Study Completion Date : May 28, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis Itching

Arm Intervention/treatment
Experimental: SHR0410
Experimental: SHR0410 dose escalation.
Drug: SHR0410
SHR0410 monotherapy,given intravenously
Other Name: KOR agonist

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [ Time Frame: Pre-dose to Day13 ]

Secondary Outcome Measures :
  1. Assessment of PK parameter-Area under drug-time curve (AUC0-t) [ Time Frame: Pre-dose to Day 6 ]
  2. Assessment of PK parameter-Area under drug-time curve (AUC0-∝) [ Time Frame: Pre-dose to Day 6 ]
  3. Assessment of PK parameter-peak time (Tmax) [ Time Frame: Pre-dose to Day 6 ]
  4. Assessment of PK parameter-peak concentration (Cmax) [ Time Frame: Pre-dose to Day 6 ]
  5. Assessment of PK parameter-half-life (t1/2) [ Time Frame: Pre-dose to Day 6 ]
  6. Assessment of PK parameter-pparent clearance rate (CL) [ Time Frame: Pre-dose to Day 6 ]
  7. Assessment of PK parameter-apparent distribution volume (Vz) [ Time Frame: Pre-dose to Day 6 ]
  8. Pharmacokinetic-The ratio of AUC0-t after the first and last administration. [ Time Frame: Pre-dose to Day 6 ]
  9. The renal clearance rate of SHR0410 in urine after each administration. [ Time Frame: Pre-dose to Day 6 ]
  10. The cumulative excretion rate of SHR0410 in urine after each administration. [ Time Frame: Pre-dose to Day 6 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able to understand the study procedures, the risks involved and obtain written informed consent before any study related activity;
  2. Male or female between the ages of 18 and 65 years, inclusive;
  3. A total body weight ≥ 50 kg;
  4. End stage of renal disease (ESRD) participants who have been on hemodialysis (including hemodiafiltration) for at least six months and are currently on hemodialysis (including hemodiafiltration) three times a week.
  5. Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, throughout the study period and for 28 days following last study drug dosing. Female subjects must be post-menopausal for at least 1 year, permanently sterilized (e.g., tubal occlusion, hysterectomy,bilateral salpingectomy) or, if of childbearing potential, must be willing to use a highly effective method of contraception throughout the study period and for 28 days following last study drug dosing, and enter the trial only after menstruation is confirmed..

Exclusion Criteria:

  1. Anticipated to receive a kidney transplant during the study;
  2. Known history of allergic reaction to opiates such as hives (Note: side effects related to the use of opioids such as constipation or nausea would not exclude the participants from the study);
  3. History of drug abuse in the past;
  4. Nicotine test positive;
  5. Alcohol breath test was positive;
  6. The average daily intake of alcohol in the three months before screening was more than 15 g (15 g alcohol equivalent to 450 ml beer or 150 ml wine or 50 ml low-alcohol liquor).
  7. Could not obey the unified dietary arrangements and avoid taking coffee or tea during the study period;
  8. Blood pressure of upper limbs in supine position was : systolic pressure < 110 mmHg, diastolic pressure < 70 mmHg or systolic pressure > 180 mmHg, diastolic pressure > 110 mmHg at screening or pre-dosing after confirmation in a repeat test;
  9. New York Heart Function Classification (NYHA) > III in the screening stage, or abnormal electrocardiogram with clinical significance judged by researchers in the screening stage , including QTcF > 480ms;
  10. Screening alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase > 1.5 × ULN, or total bilirubin> 1.5 × ULN.
  11. Positive at screening for human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody.
  12. Undergone major surgery within 3 months prior to screening.
  13. Total blood loss ≥ 200 ml within 30 days prior to screening, excluding female bleeding during physiological period.
  14. Blood human chorionic gonadotropin (hCG) test was positive.
  15. Opioids were used within a week before screening, or opioids other than research drugs could not be avoided during the study period.
  16. Previous participation in this trial, as defined by signing informed consent form;
  17. Participation defined as administration of investigational drugs in another clinical trial (including trial with medical devices) 3 months before screening, or currently participating in another clinical trial (including medical device trials);
  18. Any other medical or psychological condition, which in the opinion of the Investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements, or to complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04099927

Layout table for location information
China, Jiangsu
Zhongda Hospital Affiliated to Southeast University
Nanjing, Jiangsu, China, 210009
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for investigator information
Study Director: Jianjun Zou Jiangsu HengRui Medicine Co., Ltd.
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd. Identifier: NCT04099927    
Other Study ID Numbers: SHR0410-102
First Posted: September 23, 2019    Key Record Dates
Last Update Posted: May 22, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Skin Manifestations
Signs and Symptoms